Skip to content

Olema Pharmaceuticals, Inc. OLMA Proceeds From Issuance Of Shares Under At The Market Offering

Proceeds From Issuance Of Shares Under At The Market Offering at other companies

Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$12.11M
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
$0-100%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$137.09M
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$226.73M
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$16.4M+50.7%
Gryphon Digital Mining, Inc. logo
Gryphon Digital Mining, Inc.ABTC
$110.5M

Other financials

Income statement

See full
Operating income-$58.0M-66.3%
Net income-$53.1M-74.7%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$52.5M+3.8%
Total debt$956.0K-16.7%
Total equity$480.5M+25.3%
Total assets$530.6M+29.5%

Cash flow

See full
Operating cash flow-$46.0M-4.6%
CapEx-
Free cash flow-$34.5M-27.8%

Valuation

See full
Market cap$998.38M+253%
Enterprise value$946.79M+306%

Returns & leverage

See full
Return on equity-42.9%+1.3pp
Debt / equity0.0×
Current ratio10.9×-4.3×

Where this comes from

Reported directly by Olema Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept olma:ProceedsFromIssuanceOfSharesUnderAtTheMarketOffering.

The official record: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Olema Pharmaceuticals, Inc.'s proceeds from issuance of shares under at the market offering.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Olema Pharmaceuticals, Inc.'s proceeds from issuance of shares under at the market offering?
Olema Pharmaceuticals, Inc. (OLMA) reported proceeds from issuance of shares under at the market offering of $41.92M in Q1 2026.
What does proceeds from issuance of shares under at the market offering mean?
This captures cash proceeds from selling shares directly into the open market at prevailing market prices, often through an 'at-the-market' (ATM) facility. This provides the company with flexible, incremental access to capital without the need for a formal underwritten offering. It is a key indicator of the company's ability to manage its cash runway efficiently.